Zydus reduces COVID-19 drug Remdesivir price to Rs 899

Published On 2021-03-25 08:21 GMT   |   Update On 2021-03-25 08:21 GMT
Advertisement

Ahmedabad: In a significant move Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.

Remdac which was launched in August 2020 at Rs. 2800, continues to be India's most economical brand of Remdesivir and a critical drug in the treatment of COVID-19. This move to further revise the prices will go a long way in helping patients during these critical times.

Advertisement

Speaking on the development Dr. Sharvil Patel, Managing Director, Cadila Healthcare Limited said, "Through the course of this pandemic, our efforts have been focused on making therapies accessible and affordable to people. Remdac has been one of the critical drugs in the disease management on COVID and we hope that this price cut will enable people from every strata of the society to access this critical drug."

In June 2020, Zydus entered into a non-exclusive agreement with Gilead Sciences Inc., to manufacture and sell Remdesivir, the investigational drug, which has been issued an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of COVID 19.

The API for the drug has been developed and manufactured at the group's API manufacturing facilities in Gujarat.

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.

The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News